Lupin launches Prucalopride tablets in US
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Subscribe To Our Newsletter & Stay Updated